H. Lundbeck A/S, a pharmaceutical company, engages in the research and development, production, marketing, and sale of pharmaceuticals for the treatment of CNS disorders, including depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease and insomnia. The company’s products include Circadin for the treatment of primary insomnia; Cipralex, Lexapro, Sipralexa, Sipralex, Cipramil, Seropram, Cipram, and Celexa for the treatment of depression, generalized anxiety disorder, panic disorder, and social anxiety disorder; Ebixa and Ebix for the treatment of moderate to severe Alzheimer’s disease; Azilect for the treatment of Parkinson’s disease; Serdolect and Serlect for the treatment of schizophrenia; and Deanxit for the treatment of mild depression. The company also offers Noritren, Nortrilen, Sensaval, Saroten, Sarotex, and Redomex for depression; and Cisordinol and Clopixol to treat schizophrenia and other psychotic disorders, anxiety, restlessness, and insomnia. The company provides Cisordinol Depot, Clopixol Depot, Ciatyl-Z Depot, Fluanxol Depot, and Depixol to maintain and treat chronic psychotic disorders; and Cisordinol-Acutard, Clopixol-Acutard, Clopixol-Acuphase, and Ciatyl-Z-Acuphase for treating acute psychotic episodes and exacerbation of psychotic disorders. Its other products include Fluanxol, Fluanxol Mite, and Depixol for schizophrenia, other psychotic disorders, and mild depression; and Truxal and Truxaletten for the treatment of schizophrenia and other psychotic disorders, anxiety, restlessness, and withdrawal symptoms in drug addicts. The company has a range of products under clinical development for the treatment of mood disorders, psychoses, neurodegenerative disorders, epilepsy, sleep disorders, and stroke. Partnerships The company has partnership with BioTie Therapies Corp.; Forest Laboratories, Inc.; Merz Pharmaceuticals GmbH; Mochida Pharmaceutical Co.; neurim Pharmaceuticals Ltd.; PAIOn AG; Solvay Pharmaceuticals B.V.; Takeda Pharmaceutical Company Ltd.; Teva Pharmaceutical Industries Ltd.; and Xian-Janssen Pharmaceutical Ltd. History H. Lundbeck A/S was founded in 1915.
h lundbeck a/s (HLUKF:OTC US)
Phone: 45 36 30 13 11
Fax: 45 36 30 19 40www.lundbeck.com
|Actelion Ltd||SFr.125.20 CHF||-3.70|
|Ipsen SA||€47.55 EUR||-1.59|
|Lupin Ltd||1,791 INR||-61.80|
|Meda AB||kr143.90 SEK||+57.85|
|Recordati SpA||€20.48 EUR||+0.17|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact H LUNDBECK A/S, please visit www.lundbeck.com. Company data is provided by Capital IQ. Please use this form to report any data issues.